Skip to content
Parakho

Lupin Ltd

NSE LUPINBSE 500257lupin.com

Q1 FY27, unaudited

Revenue
₹7,171.90 Cr
Profit after tax
₹2,714.60 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations7,171.90+25.63%19,512.66
Other income102.48+89.29%312.77
Total income7,274.38+26.23%19,825.43
Employee benefit expense719.69+11.77%2,544.88
Finance costs35.56+88.15%121.47
Depreciation & amortisation190.01+7.51%707.18
Total expenses3,664.32+15.43%12,537.75
Profit before tax3,610.06+39.48%7,694.25
Tax expense895.46+94.63%1,327.69
Profit after tax2,714.60+27.56%6,366.56
Total comprehensive income2,721.66+28.01%6,349.48
Earnings per share
Earnings per share, basic₹59.37₹139.38
Earnings per share, diluted₹59.27₹139.01

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Lupin reported record quarterly revenue exceeding INR 8,000 crores and EBITDA exceeding INR 2,400 crores, marking the 16th consecutive quarter of YoY growth. Management attributed growth to strong U.S. sales, ex-U.S. organic growth of over 20% YoY, and double-digit growth across India, Other Developed Markets, and Emerging Markets. Management reiterated full-year guidance of high single-digit revenue growth with EBITDA margins of around 25%, while flagging increased competitive intensity on key U.S. products in coming quarters.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 93 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 09 Oct 2026.